Neuvivo

About Neuvivo

Neuvivo is a biotechnology company dedicated to making a meaningful difference in the lives of those battling ALS (Amyotrophic Lateral Sclerosis) by developing innovative immunologic approaches to neurodegenerative diseases. Their mission is to improve patient outcomes through science-based innovation and a strong commitment to human health.

Products & Services

NP001:An immunotherapy drug targeting the immune system to treat ALS by addressing neuroinflammation and dysfunctional innate immunity.

Specialties

Immunotherapy for ALS Neuroimmunology Neurodegenerative Disease Treatment Targeting Inflammation at Neuromuscular Junction

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Venture Financing T: - FT: Venture Financing	A: 11000000 MR: - FA: $11M FAN: 11000000	D: 2023-06-15 FD: 2023-06-15	1 investors

Venture Financing Latest

2023-06-15

$11.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Ari Azhir

Founder & CEO

M

Mike McGrath

Chief Scientific Officer

V

Vern Norviel

M

Matthew W. Davis

Chief Medical Officer

M

Mark Henderson

VP of Technical Operations

V

Virit Vichitvadakan

View 13 more team members with Pro

Unlock Full Team Directory

Recent News

Neuvivo Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised